GTHX Stock - G1 Therapeutics, Inc.
Unlock GoAI Insights for GTHX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $82.51M | $51.30M | $31.48M | $45.28M | N/A |
| Gross Profit | $75.32M | $47.55M | $29.46M | $45.28M | $-356,000 |
| Gross Margin | 91.3% | 92.7% | 93.6% | 100.0% | N/A |
| Operating Income | $-39,527,000 | $-136,178,000 | $-142,457,000 | $-96,476,000 | $-129,041,000 |
| Net Income | $-47,967,000 | $-147,559,000 | $-148,352,000 | $-99,254,000 | $-122,091,000 |
| Net Margin | -58.1% | -287.6% | -471.3% | -219.2% | N/A |
| EPS | $-0.93 | $-3.38 | $-3.54 | $-2.62 | $-3.26 |
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 30th 2023 | JP Morgan | Upgrade | Neutral | $10← $7 |
| January 3rd 2023 | Needham | Reiterated | Buy | $31← $32 |
Earnings History & Surprises
GTHXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 8, 2024 | $-0.17 | $-0.10 | +41.2% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $-0.19 | $-0.20 | -5.3% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.27 | $-0.21 | +22.2% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $-0.31 | $-0.35 | -12.9% | ✗ MISS |
Q3 2023 | Aug 2, 2023 | $-0.22 | $0.14 | +163.6% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.64 | $-0.53 | +17.2% | ✓ BEAT |
Q1 2023 | Mar 1, 2023 | $-0.85 | $-0.73 | +14.1% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.64 | $-0.59 | +7.8% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-1.04 | $-0.92 | +11.5% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.99 | $-1.15 | -16.2% | ✗ MISS |
Q1 2022 | Feb 23, 2022 | $-1.03 | $-0.94 | +8.7% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-1.03 | $-1.00 | +2.9% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.96 | $-0.94 | +2.1% | ✓ BEAT |
Q2 2021 | May 5, 2021 | $-1.09 | $-0.65 | +40.4% | ✓ BEAT |
Q1 2021 | Feb 24, 2021 | $-0.88 | $-0.67 | +23.9% | ✓ BEAT |
Q4 2020 | Nov 4, 2020 | $-0.25 | $-0.31 | -24.0% | ✗ MISS |
Q3 2020 | Aug 5, 2020 | $-0.83 | $-0.83 | 0.0% | = MET |
Q2 2020 | May 6, 2020 | $-0.98 | $-0.82 | +16.3% | ✓ BEAT |
Q1 2020 | Feb 26, 2020 | $-0.97 | $-0.94 | +3.1% | ✓ BEAT |
Q4 2019 | Nov 5, 2019 | $-0.87 | $-0.86 | +1.1% | ✓ BEAT |
Latest News
Frequently Asked Questions about GTHX
What is GTHX's current stock price?
What is the analyst price target for GTHX?
What sector is G1 Therapeutics, Inc. in?
What is GTHX's market cap?
Does GTHX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GTHX for comparison